Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | EYA2 | O00167 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652462 | 1.00 | TDP1 (0.39) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL29395464 | 1.00 | TDP1 (0.39) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL6520314 | 0.95 | SOAT1 (0.36) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL5004047 | 0.94 | CA1 (0.34) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL13814004 | 0.93 | TDP1 (0.38) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL10413971 | 0.93 | SOAT1 (0.37) | CA1CA2CA12CA9 | |
| SCHEMBL1742184 | 0.93 | SOAT1 (0.37) | CA1CA2CA12CA9 | |
| SCHEMBL12974314 | 0.90 | CA1 (0.34) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL8842200 | 0.87 | OPRD1 (0.41) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL3108023 | 0.87 | TDP1 (0.42) | TDP1EYA2APPACEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911457-B2 | Imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions. | CARBOMER, INC. (US) | 2005-06-28 | — | — | US | claimed |
| US-20030207823-A1 | Novel diabetes imaging probes | CARBOMER, INC. | 2003-11-06 | — | — | US | claimed |
| WO-2003086563-A2 | DIABETES IMAGING PROBES | CARBOMER, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| WO-1990007342-A1 | PROCESS FOR PREPARING ISOTHIOCYANATO FUNCTIONALIZED METAL COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1990-07-12 | — | — | WO | claimed |
| EP-0374947-A1 | Process for preparing isothiocyanato functionalized metal complexes | THE DOW CHEMICAL COMPANY (US) | 1990-06-27 | — | — | EP | claimed |
| US-4831175-A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-05-16 | — | — | US | claimed |
| US-20240083953-A1 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-03-14 | — | — | US | disclosed |
| US-11820795-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220127308-A1 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-11248028-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200277336-A1 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2020-09-03 | — | — | US | disclosed |
| US-10669383-B2 | Spheronized polymer particles | EVONIK CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10611803-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2000073302-A1 | OXAZAHETEROCYCLES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-1999051571-A1 | BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5412148-A | Amplifier molecules derived from diethylene triaminepentaacetic acid for enhancement of diagnosis and therapy | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1995-05-02 | — | — | US | disclosed |
| WO-1994003593-A1 | AMPLIFIER MOLECULES FOR ENHANCEMENT OF DIAGNOSIS AND THERAPY | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1994-02-17 | — | — | WO | disclosed |
| US-5252317-A | Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1993-10-12 | — | — | US | disclosed |
| US-5135737-A | Amplifier molecules for enhancement of diagnosis and therapy | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1992-08-04 | — | — | US | disclosed |
| US-5006643-A | Reacting aminofunctional chelates with thiophosgene | THE DOW CHEMICAL COMPANY (US) | 1991-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207823-A1 | Novel diabetes imaging probes | IAPP, GPR119, DPP4 | TDP1 3234/4885EYA2 2461/4885APP 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.